Introduction
============

It is widely known that patients living with type 2 diabetes (T2D) carry a high burden of psychosocial problems[@b1-tcrm-11-669] and psychological disorders.[@b2-tcrm-11-669]--[@b4-tcrm-11-669] Worrying about the future, the possibility of complications, and feelings of guilt or anxiety when "off-track" with diabetes management are reported to be sources of significant distress.[@b5-tcrm-11-669],[@b6-tcrm-11-669]

Emotional distress in people with diabetes mellitus mainly comprises diabetes-related distress (DRD) and depression.[@b7-tcrm-11-669] Among adults with T2D, DRD and depression were reported to be more prevalent and persistent than other affective disorders (anxiety, panic disorders, and dysthymia) over a period of 18 months.[@b3-tcrm-11-669] DRD is defined as patient concerns about disease management, support, emotional burden, and access to care, and is distinctively different from depression, which is not disease-specific or context-specific to diabetes care.[@b8-tcrm-11-669]--[@b10-tcrm-11-669] It was suggested from previous studies that DRD could progress to depression,[@b11-tcrm-11-669] a more severe form of emotional distress, which in turn causes poor self-care activity, disease control, morbidity, and mortality.[@b7-tcrm-11-669],[@b12-tcrm-11-669] Fisher (β=0.026)[@b10-tcrm-11-669] and Aikens (adjusted β=0.34)[@b13-tcrm-11-669] reported a cross-sectional relationship between DRD and control of glycated hemoglobin (HbA~1c~).

Since the introduction of DRD-specific scales such the Diabetes Distress Scale (DDS-17) in 2005[@b8-tcrm-11-669] and the Problem Areas In Diabetes in 1995,[@b14-tcrm-11-669] there have been increasing numbers of studies looking into the relationship between DRD and disease control in adults with T2D.[@b15-tcrm-11-669] Nevertheless, reports of patient self-reported outcome measures, such as DRD, depression, health-related quality of life (HRQoL), and medication adherence (MA) have been few in non-Western countries. As these aspects of patient are important in self-management and disease control,[@b15-tcrm-11-669]--[@b17-tcrm-11-669] it is paramount that their associations are studied in patients of other cultural backgrounds. The Asia-Pacific region including Malaysia has reported an increasing prevalence of T2D.[@b18-tcrm-11-669] Abundant local data have shown that poor disease control and suboptimal clinical management are hard to overcome.[@b19-tcrm-11-669]--[@b21-tcrm-11-669] This would inevitably lead to increased patient suffering and health care costs from diabetes-related complications.[@b22-tcrm-11-669],[@b23-tcrm-11-669]

This study examined the associations of DRD, depression, MA, and HRQoL with the three main biomarkers of risk, namely glycemia, blood pressure (BP), and lipids in adults with T2D. As part of a larger study of emotional burden and its effect on disease control, MA, and quality of life in patients with T2D (EDDMQoL), it is hoped that this study would be informative regarding the associations between these variables to improve existing therapeutic strategies or provide grounds for a potential risk management intervention in these patients.

Materials and methods
=====================

This cross-sectional study was conducted from 2012 to 2013. In addition to a questionnaire on demography (age, gender, ethnicity, types of religion, degrees of religiosity, marital status, educational level, employment status, monthly income), exercise, and smoking status, we used a structured case record form to capture comorbidity (hypertension and hyperlipidemia/dyslipidemia), diabetes-related complications, duration of diabetes, glycemic status, and BP and lipid control, along with number and types of medication used. We also used another four questionnaires to evaluate DRD, depressive symptoms (DS), MA, and HRQoL. These questionnaires were prepared in three languages, ie, English, Malay, and Mandarin.

Setting
-------

Participants were recruited from three public health clinics (Klinik Kesihatan Seri Kembangan, Klinik Kesihatan Dengkil, and Klinik Kesihatan Salak) in Malaysia. These health clinics were chosen because they are different in terms of patient sociodemographic characteristics and the geographical regions that they are situated in. The variability of the sites provided a broad range of patients in which to assess the relationships between the study variables.

Participants
------------

We consecutively sampled all patients with T2D who came to the clinics. They were at least 30 years old and had to have been diagnosed more than one year earlier. Patients were on regular follow-up, had made at least three visits in the past year, and had recent blood results within the previous 3 months. We excluded patients who were pregnant or lactating, patients who had a psychiatric/psychological disorder that could impair judgment and memory, and patients who could not read or understand English, Malay, or Mandarin. Patients who fulfilled the criteria were approached and informed of the study, and written consent was secured before answering the questionnaires in the language they preferred. This cross-sectional study was approved by the Medical Research Ethics Committee, Ministry of Health, Malaysia.

Definitions of disease
----------------------

The definition of T2D in this study was based on the following: either a documented diagnosis of T2D according to 1999 World Health Organization criteria[@b24-tcrm-11-669] or current treatment recorded in the patient's card as consisting of lifestyle modification, oral hypoglycemic agents, or insulin. This information was obtained from patient case records.

Glycemic status comprised HbA~1c~ and casual blood glucose (CBG). Hypertension was diagnosed if systolic BP was ≥130 mmHg or diastolic BP was ≥80 mmHg on each of two successive readings obtained by the clinic physicians.[@b25-tcrm-11-669] Lipid profile consisted of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and total cholesterol. Dyslipidemia refers to either an increase or decrease in concentration of one or more plasma or serum lipids (LDL-C \>2.6 mmol/L, triglycerides \>1.7 mmol/L, and HDL-C \<1.1 mmol/L).[@b25-tcrm-11-669],[@b26-tcrm-11-669] These clinical data were retrieved from the patient's medical record using a case record form on the same day as the patient completed the questionnaires.

Definitions of diabetes-related complications
---------------------------------------------

There were five diabetes-related complications in this study; three were classified as microvascular complications, ie, retinopathy, nephropathy, and diabetic foot problems; another two were classified as macrovascular complications, ie, ischemic heart disease and cerebrovascular disease or stroke. These complications were retrieved from patients' records. Diabetic foot problems comprised foot deformity, current ulcer, amputation, peripheral neuropathy, or peripheral vascular disease.

Diabetes-related distress
-------------------------

DRD was measured using the validated DDS-17.[@b8-tcrm-11-669] This instrument assesses problems and difficulties concerning diabetes during the previous month on a Likert scale from 1 (not a problem) to 6 (a very serious problem).[@b8-tcrm-11-669],[@b27-tcrm-11-669] The DDS-17 yields a total diabetes distress scale score plus four subscale scores that address different types of distress, ie, emotional burden, physician-related distress (PD), regimen-related distress, and diabetes-related interpersonal distress.[@b8-tcrm-11-669] A local translation and validation study of the Malay version of the DDS-17 showed high internal consistency (Cronbach's α=0.94), and the test-retest reliability value was 0.33 (*P*=0.009). There was a significant association between mean DDS-17 item score categories (\<3 versus ≥3) and HbA~1c~ categories (\<7% versus ≥7%, *χ*^2^=4.20; *P*=0.048). \[under a journal's review\].

Depressive symptoms
-------------------

Symptoms of depression were measured using the 9-item Patient Health Questionnaire (PHQ-9), which has been shown to have good construct and criterion validity in diagnosing and assessing the severity of depression.[@b28-tcrm-11-669] The PHQ-9 refers to symptoms experienced by patients during the 2 weeks prior to answering the questionnaire. As a severity measure, the PHQ-9 scores range from 0 to 27. A PHQ-9 score of 0--4 suggests none to minimal depression, 5--9 indicates mild depression, 10--14 indicates moderate depression, 15--19 indicates moderately severe depression, and 20--27 indicates severe depression. The Malay version of the PHQ-9 had been locally validated, with acceptable psychometric properties.[@b29-tcrm-11-669] The reported sensitivity was 87% (95% confidence interval \[CI\] 71--95), the specificity was 82% (CI 74--88), the positive likelihood ratio was 4.8 (CI 3.2--7.2), and the negative likelihood ratio was 0.16 (CI 0.06--0.40).[@b29-tcrm-11-669]

Medication adherence
--------------------

The 8-item Morisky Medication Adherence Scale (MMAS-8) was used to measure MA. The MMAS-8 is reliable (Cron-bach's α=0.83), with a sensitivity of 93% and a specificity of 53%,[@b30-tcrm-11-669] and the Malay version of the MMAS-8 has been locally validated, showing a significant relationship between MMAS-8 categories and HbA~1c~ categories (*χ*^2^=20.261; *P*≤0.001).[@b31-tcrm-11-669] The MMAS-8 enquires about patient's experiences with medications during the 2 weeks prior to answering the questionnaire. The total scale has a range of 0--8, including low adherence (\<6), medium adherence (6--7), and high adherence (8).

Health-related quality of life
------------------------------

The World Health Organization Quality of Life-Brief (WHOQOL-BREF) produces four HRQoL domains and scores,[@b32-tcrm-11-669] ie, a physical domain, a psychological domain, a social relationships domain, and an environment domain.[@b32-tcrm-11-669] There are two items that examine overall HRQoL separately: question 1 asks about an individual's overall perception of quality of life and question 2 asks about an individual's overall perception of his or her health. Higher scores denote higher quality of life. We arbitrarily categorized this variable into three using a 0--100 score, ie, 0--49.99 (low), 50.01--74.99 (medium), or 75--100 (high, [Figure 1](#f1-tcrm-11-669){ref-type="fig"}).

Statistical analysis
--------------------

The sample size was calculated using G\*Power 3.1.2 software.[@b33-tcrm-11-669] Using an estimated relationship effect of *r*=0.16 between DRD and HbA~1c~,[@b10-tcrm-11-669],[@b34-tcrm-11-669] a power of 0.95, and significance at 0.05, the estimated sample size was 500. Taking into consideration 30% of incomplete/missing data in the patient medical record and incomplete questionnaires returned from patients, the sample size needed to be increased to 650.

The data analyses were done using PASW version 21.0 (SPSS, Chicago, IL, USA). Descriptive analyses were conducted to characterize the sample, and distributions were visually and quantitatively examined for normality of distribution. Since all the independent variables included were based on past studies, we further selected potential demographic and medical confounders from the univariable analyses. The dependent variables were HbA~1c~, CBG, systolic BP, diastolic BP, LDL-C, HDL-C, triglycerides, and total cholesterol. The associations of these disease control variables were analyzed using multivariable regression analyses, with potential confounders included in the model and using the criterion of two-tailed *P*\<0.05. Missing data were not imputed because the available data and sample size were deemed adequately powered as evidence by the normal distributions of all the dependent variables as well as the main independent variables (DRD, DS, MA, and HRQoL). As the DDS-17 and PHQ-9 scores were moderately correlated (*r*=0.51, *P*\<0.0001), they were evaluated both alone and when the other was adjusted for, because their multicol-linearity could distort their individual regression coefficients. Outliers were checked with std (standardized) residual, making sure that the minimum and maximum values did not exceed ±3. There were fewer than five outliers identified in the analyses, and as all the outliers were validated, we included all of them in the analyses. All statistical assumptions were checked and confirmed within acceptable limits.

Results
=======

The participants' response rate was 93.1% (700/752). The majority were females (52.8%), Malay (52.9%), married or living with partners (79.2%), had non-tertiary education (89.1%), and were earning \<RM 3,000 per month (94.5%); most of the patients had some exercise and were non-smokers ([Table 1](#t1-tcrm-11-669){ref-type="table"}). About 80% were reported to have hypertension, but use of antihypertensives was almost 90%. A similar observation was noted for dyslipidemia, with almost doubled percentage use of lipid-lowering agents compared to the prevalence of dyslipidemia ([Table 1](#t1-tcrm-11-669){ref-type="table"}). Use of antiplatelet agents corresponded to the prevalence of complications. [Table 1](#t1-tcrm-11-669){ref-type="table"} shows the sociodemographic characteristics of the patients according to biomarkers of disease. [Table 2](#t2-tcrm-11-669){ref-type="table"} shows the differences in clinical parameters and mean scores for the DDS-17, PHQ-9, WHOQOL-BREF, and MMAS-8 in the three health clinics. [Figure 1](#f1-tcrm-11-669){ref-type="fig"} shows the proportion of patients according to the categories of DDS-17, PHQ-9, MMAS-8, and WHOQOL-BREF. DRD and DS showed a descending pattern of distribution, with most patients reported to have mild symptoms. With regard to MA, almost all patients reported low to medium adherence with their medication. In terms of HRQoL, the majority of patients experienced a medium level of quality of life ([Figure 1](#f1-tcrm-11-669){ref-type="fig"}).

In Pearson correlation analysis, the DDS-17 score correlated with systolic BP (*r*= −0.157, *P*\<0.001), diastolic BP (*r*= −0.083, *P*\<0.05), and HDL-C (*r*=0.105, *P*\<0.05). The PD subscale score showed a significant correlation with triglycerides (*r*= −0.095, *P*\<0.05) whereas the total DDS-17 score did not show any correlation. The PHQ-9 score correlated with CBG (*r*=0.087, *P*\<0.05), LDL-C (*r*=0.115, *P*\<0.001), HDL-C (*r*=0.118, *P*\<0.001), and total cholesterol (*r*=0.134, *P*\<0.001). The MMAS-8 score correlated with HbA~1c~ (*r*= −0.136, *P*\<0.001), CBG (*r*= −0.088, *P*\<0.05), diastolic BP (*r*= −0.130, *P*\<0.001), LDL-C (*r*= −0.105, *P*\<0.05), and total cholesterol (*r*= −0.136, *P*\<0.001). Total WHOQOL-BREF score correlated with CBG (*r*= −0.111, *P*\<0.001), HDL-C (*r*= −0.125, *P*\<0.001), and total cholesterol (*r*= −0.084, *P*\<0.05). Patient age showed a significant correlation with all disease control biomarkers except for CBG (Pearson *r* values ranged from −0.279 to 0.133). Diabetes duration (in years) correlated with HbA~1c~ (*r*=0.212, *P*\<0.001), CBG (*r*=0.109, *P*\<0.001), diastolic BP (*r*= −0.196, *P*\<0.001), LDL-C (*r*= −0.106, *P*\<0.05), and HDL-C (*r*=0.138, *P*\<0.001).

[Table 3](#t3-tcrm-11-669){ref-type="table"} shows the adjusted effects of DDS-17 (and PD), PHQ-9, WHOQOL-BREF, and MMAS-8 on disease bio-markers. WHOQOL-BREF had significant effect on CBG (adjusted B= −0.06, *P*=0.024). Other associations that had near significant effects included MMAS-8 on HbA~1c~, DDS-17 on systolic BP, PHQ-9 on LDL-C, PD on triglycerides, and WHOQOL-BREF and MMAS-8 on total cholesterol.

Discussion
==========

This study examined the associations of DRD, DS, HRQoL, and MA with glycemia, BP, and lipid biomarkers in adults with T2D. There have been very few studies that have investigated these four patient self-reported outcomes in adults with T2D and a multicultural Asian background or their associations with the three important disease status variables (HbA~1c~, BP, and lipids) in a single setting.

Sociodemographic characteristics, including age, gender, and ethnicity and their associations with disease control were similar to those in previous reports.[@b35-tcrm-11-669]--[@b37-tcrm-11-669] In contrast with other cross-sectional data from India,[@b38-tcrm-11-669] Japan,[@b39-tcrm-11-669] and the USA,[@b10-tcrm-11-669],[@b13-tcrm-11-669] we did not observe any association between DRD or DS and HbA~1c~. Similarly, the associations of age, gender, ethnicity, diabetes duration, and medication use with glycemia, BP, and lipid control were not in parallel with earlier registry-based studies.[@b21-tcrm-11-669],[@b35-tcrm-11-669]--[@b37-tcrm-11-669],[@b40-tcrm-11-669] This could be due to small differences in subgroups of these variables in this study or expanded power in the registry-based studies due to their very large sample size. The lack of an association between DRD and glucose biomarkers might indicate the relatively small effects of DRD, which were further diluted after adjusting for other sociodemographic variables. It is possible that DRD was a psychological state of coping (similar to the effects of DDS-17 on systolic BP, and the PD subscale on triglycerides, see below) and not related to failure of self-management that could affect HbA~1c~. Further studies are needed to look into the role of DRD in self-management of diabetes in patients with different sociocultural backgrounds, relationship to illness perception, coping, MA, and HRQoL.[@b41-tcrm-11-669]

The most intriguing results in this study were the higher DRD and the lower systolic BP, higher PD, and lower triglycerides. This consistent trend of DRD with disease biomarkers was marked, with the PD subscale showing the highest (among the DDS-17, PHQ-9, and MMAS-8) and most consistent negative correlation with HbA~1c~, systolic and diastolic BP, and triglycerides. A plausible explanation for these observations is that DRD might indicate a state of psychological reaction or active coping by patients, resulting in heightened self-management. It is not uncommon for doctors in health clinics to become impatient with patients who do not adhere to advice, talk less even when patients ask for more explanation, and display indifference to patients during busy clinic days.[@b42-tcrm-11-669],[@b43-tcrm-11-669] In these situations, health conscious and capable patients might become distressed, which in turn motivates themselves towards self-care. This indirect and apparent effect of DRD on systolic BP, which is a form of psychological distress related to diabetes management, needs further investigation. Earlier studies reported that DRD was associated with poor diabetes self-care,[@b44-tcrm-11-669]--[@b46-tcrm-11-669] and to our best knowledge, none of these studies had made a similar association between DRD and systolic BP. Further research is needed to confirm this hypothesis, and should include measures that assess self-care activity, self-efficacy, coping, and physician behaviors at the same time.

Compared with the DDS-17, which assesses diabetes-specific emotional distress, the PHQ-9 which measures DS and thus implies higher severity of an emotional distress,[@b7-tcrm-11-669] had shown more associations with the disease biomarkers. The presence of stronger associations between the PHQ-9, LDL-C, and total cholesterol suggests that DS affects lipid control more than DRD. A similar finding was reported in the USA, ie, after multivariable analysis, DRD was associated only with HbA~1c~ and not with BP or LDL-C.[@b47-tcrm-11-669] However, in a study from Lithuania, significant correlations were found between scores for emotional state (tension-anxiety, depression-dejection, and confusion-bewilderment) and lipid levels (total cholesterol, triglycerides, and low-density lipoprotein cholesterol) in patients with T2D, especially women.[@b48-tcrm-11-669] It is less clear whether there is any physiological link between DRD or DS and lipid metabolism compared to that is known between these emotional distress with glucose and BP.[@b12-tcrm-11-669],[@b49-tcrm-11-669] Hence, DRD or DS might influence disease control through changed self-care activity[@b50-tcrm-11-669] and health behavior, such as dietary choices, physical exercise, and adherence with therapy.[@b51-tcrm-11-669] It was possible that factors related to the local health clinics themselves, such as accessibility, comfort, health care system, attitudes of health care providers, and availability of drugs[@b52-tcrm-11-669] could affect disease control, as shown by a further reduction in effect size (\>10%) after controlling for the health clinic variable.

The results for MA and disease control was consistent with those of previous studies showing a prevalent association and positive effects of MA on disease control biomarkers.[@b53-tcrm-11-669],[@b54-tcrm-11-669] Higher MA was consistently shown to be associated with HbA~1c~, CBG, LDL-C, and total cholesterol. The direct and potent effects of medications on these biomarkers would be expected. However, loss of MA's effects after controlling for covariates would suggest that disease control is multifactorial.[@b54-tcrm-11-669] Indirectly, the results of this study show that other outcome measures or confounders should also be considered for DRD and DS in achieving disease control, such as diabetes self-care activity, HRQoL, and diabetes-specific quality of life.[@b55-tcrm-11-669],[@b56-tcrm-11-669] In other words, holistic diabetes care that considers both appropriate use of medications and supporting the psychological states/behaviors of patients would constitute effective diabetes care.

HRQoL as measured by WHOQOL-BREF was the only variable that had a significant effect on CBG after controlling for the other covariates. The other near significant effect of HRQoL was on total cholesterol. It is not unexpected that better HRQoL contributes to better glycemic and lipid control. Previous studies have reported a prevalent association of poor HRQoL with high HbA~1c~, BP, and lipids.[@b57-tcrm-11-669]--[@b59-tcrm-11-669] In addition to the probable mechanisms mentioned above, it is possible that HRQoL itself could have salutogenic effects on disease control.[@b60-tcrm-11-669] This means that patients with better HRQoL would be more capable in terms of self-management, emotional well-being, and social engagement. These attributes would further translate into better health literacy and adherence to therapy, and lead to better disease control. However, the selective effect of HRQoL on CBG is hard to explain in this study. We hypothesize that patients with higher HRQoL adopt selective self-management measures depending on their perceived needs. They might implement glucose control measures more strongly in days leading up to a medical visit at the health clinic but be less stringent at other times. This possibility is suggested by the negative correlation between WHOQOL-BREF score and other disease control biomarkers. However, the small effect sizes of these observations in spite of the relatively large sample size in this study casts doubt regarding the presence of any real or clinically significant relationship between HRQoL and disease control in relatively healthy adult patients with T2D attending these public health clinics.

Limitations and strengths
-------------------------

There are some limitations to this study. The strict inclusion criteria might have led to selection of a study population that was healthier, more adherent, and had better disease control, given that patients who do not turn up regularly for their appointments or have recent blood investigations might consist of those with poorer psychological well being and disease control. In addition, missing data could have been occurred in differential ways across the different category of outcomes, and as such, complete case analyses strategy as adopted in this study might affect the results and conclusions. However, we believe these biases are minimal, given that the distributions (distributions) of DRD, DS, HRQoL, and MA were all normal, and the distributions of disease control biomarkers were also normally distributed, indicating inclusion of a spectrum of disease biomarkers in the study population. The DDS-17, used in this study to measure DRD, may have inadequacies similar to those found with many standardized measures of diabetes distress,[@b14-tcrm-11-669] including lack of comprehensiveness with regard to assessment of sources of diabetes distress; for example, distress attributable to starting insulin, emergence of a new complication, or the accumulated demands and burdens of self-care. This problem might have constrained the scope of T2D's impacts on the patients.

The strength of this study includes its real-world setting, high response rate, and good sample size. A further strength is that the study population is representative of the wider T2D patient population in this country, which enables generalization of the current findings.[@b61-tcrm-11-669]

Conclusion
==========

This study has shown associations of DRD, DS, HRQoL, and MA with glycemia, BP, and lipid biomarkers in adults with T2D at the primary care level. DS, MA, and HRQoL showed the expected associations with many disease biomarkers, except between DRD and BP. Efforts to increase MA may improve disease control more effectively than psychological interventions for DRD and DS. Therefore, the effects of DRD, DS, and HRQoL on MA are worthy of further study. DRD and DS had different effects on disease control, and might need different professional support. Lastly, the possible beneficial and therapeutic effects of DRD on BP require further study to determine the possible mechanisms underpinning this relationship.
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![Proportion of patients according to the categories of diabetes-related distress, depressive symptoms, medication adherence, and health-related quality of life.\
**Abbreviations:** DDS, Diabetes Distress Scale 17 items (low, no distress, mean DDS score \<2; medium, moderate distress, mean DDS score 2--2.9; high, distress worthy of clinical attention, mean DDS score ≥3); PHQ, Patient Health Questionnaire 9 items (depression severity: low, no depression; PHQ score 0--4; medium, mild depression, PHQ score 5--9; high, moderate to severe depression, PHQ score 10--27); MMAS, Morisky Medication Adherence Scale 8 items (low, low adherence, MMAS score \<6; medium, medium adherence, MMAS score 6--7; high, high adherence, MMAS score 8); WHOQOL-BREF, World Health Organization Quality of Life-Brief (low, 0--49.99; medium, 50.01--74.99; high, 7--100. WHOQOL-BREF categories are arbitrarily set).](tcrm-11-669Fig1){#f1-tcrm-11-669}

###### 

Sociodemographic characteristic according to the health clinics

                                         Total        HbA~1c~ (%)   CBG (mmol/L)   SBP (mmHg)   DBP (mmHg)      LDL-C           HDL-C          TG            Total-C                                                                                                    
  ------------------------ ------------- ------------ ------------- -------------- ------------ --------------- --------------- -------------- ------------- -------------- ----------- ------------ ------------ -------------- ----------- -------------- ----------- -----------
  Gender                   Female        368          8.4 (2.0)     0.253          9.4 (3.6)    0.638           137.0 (17.6)    0.902          78.8 (12.0)   0.381          3.0 (1.0)   0.084        1.0 (0.3)    \<**0.0001**   1.8 (1.0)   **0.003**      4.9 (1.1)   0.119
  Male                     329           8.6 (2.3)                  9.5 (3.8)                   136.8 (17.8)                    79.6 (12.3)                  2.9 (1.0)                  0.9 (0.3)                 2.1 (1.6)                  4.7 (1.2)                  
  Ethnicity                Malay         367          8.4 (2.2)     0.138          9.5 (3.9)    0.753           138.6 (17.9)    **0.020**      81.0 (12.8)   \<**0.0001**   3.1 (1.0)   0.136        0.9 (0.3)    \<**0.0001**   2.0 (1.3)   0.214          4.9 (1.2)   0.587
  Chinese                  162           8.3 (1.8)                  9.3 (3.2)                   136.1 (16.0)                    75.6 (11.5)                  2.9 (0.9)                  1.1 (0.4)                 1.8 (0.9)                  4.8 (1.0)                  
  Indian                   165           8.8 (2.2)                  9.6 (3.7)                   134.2 (18.5)                    78.5 (10.6)                  2.9 (1.0)                  0.9 (0.3)                 2.0 (1.5)                  4.8 (1.1)                  
  Aborigine                3             7.8 (1.6)                  8.3 (1.8)                   125.7 (7.4)                     77.7 (2.1)                   1.6 (0.5)                  0.7 (0.2)                 2.0 (1.0)                  3.2 (0.5)                  
  Others                   3             7.1 (0.9)                  5.5 (1.1)                   130.7 (13.3)                    77.0 (14.1)                  2.3 (0.6)                  0.9 (0.2)                 1.4 (0.5)                  3.8 (0.6)                  
  Religion                 No religion   33           8.7 (1.8)     0.494          8.6 (3.2)    0.457           133.0 (14.6)    0.053          73.5 (9.2)    \<**0.0001**   2.8 (0.8)   0.147        1.2 (0.4)    \<**0.0001**   1.6 (0.7)   0.066          4.7 (0.8)   0.223
  Moslem                   375           8.4 (2.2)                  9.5 (3.9)                   138.6 (17.9)                    80.9 (12.9)                  3.1 (1.0)                  0.9 (0.3)                 2.0 (1.3)                  4.9 (1.2)                  
  Buddhist                 82            8.3 (2.0)                  9.9 (3.5)                   137.0 (16.4)                    76.4 (12.1)                  3.0 (1.0)                  1.1 (0.5)                 1.9 (1.1)                  5.0 (1.0)                  
  Hindu/Sikh               149           8.7 (2.7)                  9.4 (3.6)                   133.6 (18.5)                    78.1 (10.2)                  3.0 (1.1)                  0.9 (0.2)                 2.1 (1.5)                  4.8 (1.2)                  
  Christian/Catholic       22            8.8 (2.7)                  9.1 (3.2)                   134.5 (14.7)                    80.0 (13.2)                  2.5 (0.6)                  1.0 (0.3)                 1.3 (0.6)                  4.3 (0.7)                  
  Others                   37            8.1 (1.7)                  8.7 (2.6)                   136.5 (16.3)                    75.2 (10.4)                  2.7 (1.0)                  1.1 (0.3)                 1.7 (0.7)                  4.6 (1.1)                  
  Religiosity              Very agree    294          8.6 (2.2)     0.586          9.5 (3.5)    0.334           137.5 (18.5)    0.744          80.4 (12.9)   0.065          3.1 (1.1)   0.404        1.0 (0.3)    \<**0.0001**   2.0 (1.5)   0.272          4.9 (1.3)   0.542
  Agree                    301           8.3 (2.2)                  9.5 (3.9)                   137.1 (17.6)                    78.7 (10.9)                  2.9 (0.9)                  0.9 (0.3)                 2.0 (1.2)                  4.7 (1.0)                  
  Not sure                 25            8.6 (1.5)                  10.0 (3.0)                  133.4 (16.0)                    78.0 (11.3)                  2.8 (0.9)                  1.0 (0.3)                 2.1 (1.2)                  4.9 (1.0)                  
  Disagree                 73            8.4 (1.8)                  8.6 (3.2)                   135.4 (15.6)                    75.9 (14.0)                  3.0 (0.9)                  1.2 (0.4)                 1.6 (0.6)                  4.9 (1.0)                  
  Very disagree            3             9.5 (0.9)                  9.6 (2.0)                   133.0 (2.6)                     80.0 (6.1)                   2.9 (1.7)                  1.0 (0.2)                 2.0 (1.1)                  4.8 (1.4)                  
  Marital status           Married       548          8.6 (2.2)     0.067          9.5 (3.7)    0.123           136.8 (17.7)    0.942          79.9 (12.1)   **0.024**      3.0 (1.0)   0.642        1.0 (0.3)    **0.039**      2.0 (1.3)   0.216          4.8 (1.2)   0.152
  Living with a partner    3             8.1 (2.7)                  11.0 (4.3)                  128.3 (14.6)                    73.7 (6.7)                   2.5 (0.2)                  1.0 (0.1)                 1.3 (0.8)                  4.9 (1.3)                  
  Divorced                 13            8.9 (2.5)                  8.6 (3.1)                   138.2 (16.0)                    77.8 (9.5)                   3.2 (1.3)                  1.1 (90.3)                2.7 (2.4)                  5.7 (1.7)                  
  Widowed                  98            8.0 (1.9)                  9.1 (3.6)                   138.0 (18.8)                    75.3 (12.3)                  3.0 (0.9)                  1.0 (0.4)                 1.7 (0.9)                  4.8 (1.0)                  
  Separated                8             10.2 (2.4)                 11.2 (3.0)                  135.5 (23.1)                    79.8 (15.0)                  3.0 (1.1)                  1.0 (0.2)                 2.2 (1.4)                  5.0 (1.0)                  
  Single                   26            7.9 (1.6)                  7.9 (2.6)                   137.3 (15.1)                    80.5 (12.2)                  2.7 (0.8)                  1.1 (0.6)                 1.9 (1.3)                  4.5 (0.8)                  
  Educational level        Primary       259          8.4 (2.2)     0.807          9.4 (3.4)    0.870           137.2 (19.6)    0.673          77.3 (12.4)   **0.003**      2.9 (1.0)   0.466        1.0 (0.3)    \<**0.0001**   1.8 (1.2)   0.206          4.7 (1.1)   0.181
  Secondary                310           8.6 (2.2)                  9.5 (4.0)                   136.2 (16.9)                    80.2 (11.9)                  3.0 (1.0)                  1.0 (0.3)                 2.0 (1.4)                  4.9 (1.2)                  
  Tertiary                 75            8.5 (1.8)                  9.3 (3.3)                   136.8 (15.8)                    82.2 (11.7)                  3.1 (1.0)                  0.9 (0.20)                2.2 (1.5)                  4.9 (1.3)                  
  Others                   45            8.5 (2.0)                  9.8 (3.9)                   139.5 (14.9)                    77.1 (11.9)                  2.9 (1.0)                  1.2 (0.6)                 1.9 (0.7)                  4.9 (1.0)                  
  Employment status        Employed      315          8.7 (2.3)     0.166          9.4 (3.7)    0.632           135.3 (17.8)    0.054          80.7 (12.9)   **0.004**      3.0 (1.1)   0.254        0.9 (90.3)   **0.007**      2.1 (1.5)   **0.050**      4.9 (1.3)   0.600
  Unemployed               11            8.7 (1.3)                  9.7 (3.3)                   130.5 (21.2)                    81.5 (15.1)                  3.2 (0.6)                  0.8 (0.1)                 2.3 (1.3)                  5.0 (0.8)                  
  Retired                  172           8.3 (1.9)                  9.7 (3.7)                   137.5 (18.4)                    76.6 (10.6)                  2.8 (1.0)                  1.0 (0.4)                 2.0 (1.2)                  4.7 (1.1)                  
  Home manager             199           8.3 (2.1)                  9.2 (3.6)                   139.3 (16.5)                    78.7 (11.8)                  3.0 (1.0)                  1.0 (0.3)                 1.7 (0.9)                  4.8 (1.1)                  
  Income (RM)              No income     157          8.3 (2.1)     0.703          9.2 (3.2)    0.742           138.0 (17.9)    0.405          75.3 (11.3)   \<**0.0001**   2.8 (0.9)   0.228        1.0 (0.4)    0.115          1.8 (1.0)   0.412          4.7 (1.1)   0.254
  \<1,000                  170           8.5 (2.1)                  9.5 (4.0)                   138.2 (919.4)                   79.4 (12.3)                  3.0 (1.0)                  1.0 (0.3)                 2.0 (1.5)                  4.8 (1.2)                  
  1,000--2,999             235           8.5 (2.3)                  9.3 (3.5)                   135.3 (17.1)                    80.2 (12.8)                  3.0 (1.0)                  0.9 (0.2)                 2.0 (1.4)                  4.9 (1.3)                  
  3,000--4,999             87            8.7 (2.1)                  9.9 (3.8)                   135.5 (14.6)                    82.4 (10.4)                  3.1 (1.1)                  1.0 (0.3)                 2.0 (1.3)                  4.9 (1.2)                  
  ≥5,000                   38            8.3 (1.6)                  9.6 (3.3)                   136.8 (15.5)                    79.6 (11.8)                  3.0 (0.8)                  1.0 (0.3)                 1.6 (0.5)                  4.7 (0.8)                  
  Exercise                 No            295          8.6 (2.2)     0.443          9.5 (3.9)    0.481           137.7 (17.8)    0.309          79.9 (12.2)   \<**0.0001**   2.9 (1.0)   0.071        0.9 (0.3)    0.080          2.0 (1.3)   0.325          4.8 (1.1)   **0.046**
  ≤3 times/week            232           8.4 (2.2)                  9.6 (3.6)                   137.2 (17.5)                    80.4 (11.8)                  3.1 (1.0)                  1.0 (0.3)                 2.0 (1.4)                  5.0 (1.2)                  
  \>3 times/week           169           8.3 (2.0)                  9.1 (3.4)                   135.1 (17.8)                    75.8 (12.1)                  2.9 (1.0)                  1.0 (0.4)                 1.8 (1.0)                  4.7 (1.2)                  
  Smoking                  Never         532          8.4 (2.1)     0.177          9.4 (3.5)    0.983           137.0 (917.6)   0.808          79.3 (11.9)   0.804          3.0 (1.0)   0.109        1.0 (0.3)    0.163          1.9 (1.3)   0.393          4.9 (1.1)   0.375
  Stopped ≤5 years         22            9.1 (2.8)                  9.3 (5.6)                   139.8 (23.2)                    80.5 (13.2)                  2.7 (0.8)                  1.0 (0.4)                 2.3 (2.7)                  5.0 (1.6)                  
  Stopped \>5 years        60            8.1 (2.3)                  9.5 (4.0)                   136.1 (15.7)                    77.9 (12.2)                  2.7 (1.2)                  0.9 (0.2)                 2.1 (1.3)                  4.6 (1.4)                  
  Yes                      83            8.7 (2.0)                  9.6 (3.7)                   135.9 (18.0)                    79.0 (13.7)                  2.9 (1.0)                  1.0 (0.4)                 2.1 (1.0)                  4.8 (1.1)                  
  Alcohol consumption      Never         607          8.5 (2.2)     0.359          9.5 (3.7)    0.692           137.0 (17.9)    0.615          79.1 (12.0)   0.844          3.0 (1.0)   0.358        1.0 (0.3)    0.106          1.9 (1.3)   0.296          4.8 (1.2)   0.105
  Yes                      45            8.4 (1.8)                  9.3 (3.7)                   134.5 (17.8)                    78.7 (13.5)                  3.0 (1.1)                  1.1 (0.5)                 2.2 (1.4)                  5.0 (1.1)                  
  Stopped drinking         46            8.0 (1.8)                  9.0 (3.5)                   137.8 (15.1)                    80.1 (13.9)                  2.7 (0.9)                  0.9 (0.2)                 1.8 (0.8)                  4.5 (0.9)                  
  Hypertension             No            149          8.9 (2.1)     **0.024**      10.1 (4.6)   **0.014**       130.3 (15.4)    \<**0.0001**   79.2 (13.2)   0.932          3.1 (0.9)   0.112        0.9 (0.3)    0.051          1.8 (1.3)   0.193          4.9 (1.2)   0.383
  Yes                      539           8.4 (2.1)                  9.3 (3.3)                   138.9 (17.8)                    79.2 (11.8)                  2.9 (1.0)                  1.0 (0.3)                 2.0 (1.3)                  4.8 (1.2)                  
  Dyslipidemia             No            408          8.4 (2.1)     0.465          9.6 (3.9)    0.199           139.3 (18.4)    \<**0.0001**   81.6 (12.6)   \<**0.0001**   3.0 (0.9)   0.277        0.9 (0.3)    \<**0.0001**   2.0 (1.4)   0.544          4.8 (1.2)   0.929
  Yes                      265           8.6 (2.2)                  9.2 (3.2)                   133.5 (16.0)                    75.6 (10.5)                  2.9 (1.1)                  1.0 (0.3)                 1.9 (1.2)                  4.8 (1.2)                  
  Stroke/TIA               No            681          8.5 (2.1)     0.288          9.4 (3.7)    0.790           136.8 (17.7)    0.239          79.2 (12.2)   0.974          3.0 (1.0)   0.363        1.0 (0.3)    0.386          1.9 (1.3)   0.886          4.8 (1.2)   0.699
  Yes                      14            7.8 (2.0)                  9.2 (3.0)                   142.4 (16.1)                    79.1 (11.9)                  2.6 (1.2)                  0.9 (0.1)                 2.0 (0.8)                  4.7 (1.3)                  
  Ischemic heart disease   No            662          8.5 (2.2)     0.816          9.4 (3.6)    0.488           136.8 (17.8)    0.430          79.3 (12.2)   0.202          3.0 (1.0)   **0.048**    1.0 (0.3)    0.509          1.9 (1.3)   0.784          4.8 (1.2)   **0.042**
  Yes                      31            8.4 (1.6)                  9.9 (5.1)                   139.3 (15.7)                    76.5 (11.4)                  2.6 (90.9)                 0.9 (0.5)                 2.0 (0.7)                  4.4 (1.1)                  
  Retinopathy              No            680          8.4 (2.1)     **0.013**      9.4 (3.7)    0.858           136.9 (17.8)    0.986          79.3 (12.2)   0.136          3.0 (1.0)   0.191        1.0 (0.3)    **0.015**      1.9 (1.3)   0.589          4.8 (1.2)   0.459
  Yes                      19            9.7 (2.2)                  9.6 (3.5)                   136.8 (14.5)                    75.1 (10.5)                  2.7 (1.1)                  1.2 (0.8)                 1.8 (0.9)                  4.6 (1.2)                  
  Nephropathy              No            670          8.5 (2.2)     0.350          9.4 (3.7)    0.689           136.8 (17.7)    0.807          79.2 (12.2)   0.655          3.0 (1.0)   0.404        1.0 (0.3)    0.566          1.9 (1.3)   0.997          4.8 (1.2)   0.569
  Yes                      23            8.9 (1.7)                  9.7 (3.5)                   137.7 (17.3)                    78.0 (9.6)                   2.8 (1.1)                  1.0 (0.7)                 1.9 (1.2)                  4.7 (1.1)                  
  Diabetic foot problems   No            672          8.5 (2.1)     0.994          9.5 (3.7)    0.065           137.1 (17.7)    0.071          79.4 (12.3)   **0.019**      3.0 (1.0)   0.146        1.0 (0.3)    **0.047**      1.9 (1.2)   0.148          4.8 (1.2)   0.107
  Yes                      22            8.5 (2.0)                  8.0 (3.1)                   130.2 (15.3)                    73.2 (7.3)                   2.6 (0.9)                  0.8 (0.1)                 2.4 (2.2)                  4.4 (1.1)                  
  OHA                      No            61           9.0 (2.5)     **0.041**      10.1 (4.3)   0.128           144.1 (20.2)    **0.001**      78.2 (11.4)   0.504          3.2 (1.2)   0.064        0.9 (0.2)    0.257          2.3 (1.4)   **0.040**      5.2 (1.3)   **0.009**
  Yes                      634           8.4 (2.1)                  9.4 (3.6)                   136.2 (17.3)                    79.3 (12.3)                  2.9 (1.0)                  1.0 (0.3)                 1.9 (1.3)                  4.8 (1.2)                  
  Insulin                  Nil           423          7.7 (1.7)     \<**0.0001**   8.6 (3.0)    \<**0.0001**    136.1 (16.9)    0.075          80.1 (12.6)   \<**0.0001**   3.0 (0.9)   **0.015**    1.0 (0.3)    0.433          1.7 (0.9)   \<**0.0001**   4.7 (1.0)   **0.004**
  1 type                   191           9.6 (2.1)                  10.5 (3.4)                  136.6 (19.0)                    77.1 (10.6)                  2.9 (1.1)                  1.0 (0.4)                 2.3 (1.6)                  4.9 (1.3)                  
  2 types                  69            10.2 (2.3)                 11.7 (5.5)                  141.1 (18.5)                    77.6 (12.6)                  3.3 (1.0)                  0.9 (0.2)                 2.3 (2.0)                  5.3 (1.4)                  
  ≥3 types                 11            8.8 (1.7)                  10.8 (5.6)                  144.8 (10.6)                    90.8 (10.1)                  3.5 (1.3)                  0.8 (0.2)                 1.9 (0.8)                  5.1 (1.5)                  
  Number of AHA agents     Nil           82           8.7 (2.1)     0.530          10.1 (4.6)   **0.038**       125.7 (14.0)    \<**0.0001**   78.0 (14.5)   0.192          3.2 (1.0)   0.209        1.0 (0.3)    0.154          1.7 (1.4)   0.057          4.9 (1.1)   0.630
  1 type                   206           8.6 (2.1)                  9.3 (3.5)                   132.8 (14.5)                    77.8 (10.6)                  3.0 (1.0)                  1.0 (0.3)                 1.8 (1.0)                  4.8 (1.1)                  
  2 types                  204           8.3 (2.1)                  8.9 (93.3)                  137.3 (16.4)                    79.7 (11.7)                  2.9 (1.0)                  1.0 (0.3)                 1.9 (91.1)                 4.7 (1.1)                  
  3 types                  144           8.3 (2.3)                  9.8 (3.5)                   143.8 (18.5)                    80.6 (12.8)                  2.9 (1.0)                  1.0 (0.4)                 2.2 (1.7)                  4.9 (1.3)                  
  ≥4 types                 58            8.5 (2.0)                  9.9 (4.0)                   148.2 (21.5)                    80.2 (13.4)                  3.1 (1.1)                  0.9 (0.2)                 2.1 (91.3)                 4.9 (1.1)                  
  Number of LLA agents     Nil           156          8.5 (2.1)     0.773          9.7 (4.1)    0.417           137.4 (17.8)    0.125          81.2 (13.8)   0.051          3.1 (0.8)   0.111        1.0 (0.3)    0.608          1.7 (0.8)   **0.035**      4.8 (0.9)   0.981
  1 type                   534           8.5 (2.1)                  9.3 (3.5)                   136.6 (17.6)                    78.6 (11.7)                  2.9 (1.0)                  1.0 (90.3)                2.0 (1.4)                  4.8 (1.2)                  
  2 types                  4             9.3 (1.0)                  11.2 (93.9)                 154.3 (15.5)                    76.3 (7.9)                   2.3 (0.7)                  0.8 (0.4)                 2.1 (1.3)                  4.9 (1.8)                  
  Number of APA agents     Nil           616          8.4 (2.1)     0.656          9.5 (93.7)   0.686           137.1 (17.8)    0.644          79.8 (12.2)   \<**0.0001**   3.0 (1.0)   0.900        1.0 (0.3)    0.560          1.9 (1.3)   0.866          4.9 (1.2)   0.291
  1 type                   74            8.7 (2.3)                  9.2 (93.6)                  135.1 (16.6)                    74.1 (10.7)                  2.7 (0.9)                  1.0 (0.3)                 2.0 (1.4)                  4.6 (1.2)                  
  2 types                  2             8.0 (0.6)                  7.9 (3.2)                   140.5 (20.5)                    69.0 (1.4)                   2.6 (0.5)                  0.8 (0.1)                 2.0 (0.9)                  4.4 (0.8)                  

**Note:** *P*-values were for the independent *t*-test and analysis of variance. The bold *P*-values signify those that were below the significant cut-off value of \<0.05.

**Abbreviations:** CBG, casual blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; OHA, oral hypoglycemic agent; AHA, antihypertensive agent; LLA, lipid-lowering agent; APA, antiplatelet agent; SD, standard deviation; TG, triglycerides; TIA, transient ischemic attack.

###### 

Clinical variables according to the health clinics

                                  Health clinic, mean (SD) \[valid n\]   *F*                    *P*-value                                             
  ------------------------------- -------------------------------------- ---------------------- ---------------------- ---------------------- ------- ----------
  Age (years)                     56.9 (10.18) \[698\]                   58.8 (10.21) \[222\]   57.7 (11.08) \[123\]   55.5 (9.64) \[353\]    7.81    \<0.0001
  Diabetes duration (years)       6.5 (5.71) \[677\]                     9.1 (7.05) \[220\]     6.3 (4.34) \[123\]     4.9 (4.43) \[334\]     39.94   \<0.0001
  HPT duration (years)            6.8 (5.80) \[515\]                     8.4 (6.25) \[171\]     7.0 (4.59) \[108\]     5.6 (5.67) \[236\]     12.60   \<0.0001
  Dyslipidemia duration (years)   4.2 (3.01) \[250\]                     4.9 (3.33) \[124\]     3.4 (2.28) \[113\]     5.1 (3.68) \[13\]      8.87    \<0.0001
  HbA~1c~ (%)                     8.5 (2.14) \[621\]                     8.5 (2.05) \[190\]     8.6 (2.21) \[121\]     8.4 (2.16) \[310\]     0.13    0.878
  CBG (mmol/L)                    9.4 (3.66) \[687\]                     9.1 (3.12) \[219\]     9.3 (3.37) \[123\]     9.7 (4.05) \[345\]     2.00    0.137
  SBP (mmHg)                      136.9 (17.7) \[695\]                   134.5 (15.1) \[219\]   131.1 (17.0) \[123\]   140.5 (18.6) \[353\]   16.71   \<0.0001
  DBP (mmHg)                      79.2 (12.2) \[695\]                    76.6 (11.0) \[219\]    76.4 (9.3) \[123\]     81.7 (13.2) \[353\]    16.57   \<0.0001
  LDL-C (mmol/L)                  3.0 (1.00) \[566\]                     3.0 (1.04) \[201\]     2.8 (1.11) \[121\]     3.0 (0.90) \[244\]     1.70    0.184
  HDL-C in mmol/L                 1.0 (0.32) \[569\]                     1.2 (0.32) \[202\]     0.9 (0.32) \[122\]     0.9 (0.26) \[245\]     59.24   \<0.0001
  Triglycerides (mmol/L)          1.9 (1.39) \[569\]                     1.8 (1.07) \[201\]     2.0 (1.01) \[123\]     2.0 (1.54) \[245\]     2.53    0.081
  Total cholesterol (mmol/L)      4.8 (1.17) \[619\]                     5.0 (1.09) \[203\]     4.7 (1.21) \[123\]     4.8 (1.20) \[293\]     2.51    0.082
  **DDS-17**                      37.1 (15.98) \[663\]                   40.6 (17.34) \[206\]   40.3 (18.46) \[118\]   33.8 (13.35) \[339\]   14.93   \<0.0001
  Emotional burden                11.9 (5.33) \[685\]                    11.9 (5.65) \[219\]    12.6 (6.03) \[120\]    11.6 (4.84) \[346\]    1.30    0.274
  Physician distress              7.9 (4.67) \[683\]                     9.6 (5.67) \[216\]     9.1 (4.68) \[121\]     6.4 (3.29) \[346\]     40.49   \<0.0001
  Regimen distress                11.3 (5.20) \[690\]                    12.0 (5.36) \[218\]    12.2 (6.06) \[121\]    10.6 (4.65) \[351\]    7.88    \<0.0001
  Interpersonal distress          6.3 (3.65) \[689\]                     7.2 (4.40) \[217\]     7.0 (3.95) \[121\]     5.6 (2.77) \[351\]     16.15   \<0.0001
  **PHQ-9**                       4.6 (4.31) \[684\]                     5.5 (4.91) \[218\]     4.2 (4.01) \[121\]     4.2 (3.90) \[345\]     7.69    \<0.0001
  **MMAS-8**                      5.6 (1.42) \[668\]                     5.6 (1.45) \[216\]     5.8 (1.31) \[121\]     5.6 (1.45) \[331\]     0.76    0.469
  **WHOQOL-BREF**                 55.5 (6.31) \[694\]                    54.9 (6.66) \[218\]    55.0 (6.11) \[123\]    56.0 (6.12) \[353\]    2.70    0.068
  Physical health                 13.1 (1.70) \[700\]                    12.8 (1.80) \[224\]    13.1 (1.65) \[123\]    13.3 (1.64) \[353\]    5.22    0.006
  Psychological health            13.3 (1.88) \[697\]                    13.0 (1.91) \[221\]    12.7 (2.03) \[123\]    13.6 (1.73) \[353\]    12.94   \<0.0001
  Social relationship             14.7 (2.40) \[698\]                    14.7 (2.50) \[222\]    15.3 (2.45) \[123\]    14.5 (2.29) \[353\]    5.82    0.003
  Environmental                   14.4 (2.08) \[697\]                    14.3 (2.47) \[221\]    13.9 (1.89) \[123\]    14.7 (1.83) \[353\]    8.19    \<0.0001

**Note:** *P*-values are for the analysis of variance.

**Abbreviations:** DDS-17, Diabetes Distress Scale 17 items; PHQ-9, Patient Health Questionnaire 9 items; MMAS-8, 8-item Morisky Medication Adherence Scale; WHOQOL-BREF, World Health Organization Quality of Life-Brief 26 items; CBG, casual blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HPT, hypertension; SD, standard deviation; HbA~1c~, glycated hemoglobin.

###### 

Determinants of disease biomarkers

  Model                   Crude B (95.0% CI)       Adjusted B (95.0% CI)                                       Adjusted B (95.0% CI)       Significance   Adjusted *R*^2^
  ----------------------- ------------------------ ----------------------------------------------------------- --------------------------- -------------- -----------------
  **HbA**~1c~                                      **n**=**441**[\*](#tfn6-tcrm-11-669){ref-type="table-fn"}   **n**=**441**\*\*                          
  Intercept               --                       --                                                          9.77 (8.488, 11.053)        \<0.0001       0.308
  MMAS-8                  −0.21 (−0.329, −0.085)   −0.10 (−0.224, 0.018)                                       −0.11 (−0.224, 0.014)       0.082          
  **CBG**                                          **n**=**613**[†](#tfn7-tcrm-11-669){ref-type="table-fn"}    **n**=**613**^††^                          
  Intercept               --                       --                                                          14.83 (11.526, 18.128)      \<0.0001       0.110
  PHQ-9                   0.07 (0.010, 0.139)      0.01 (−0.067, 0.077)                                        0.01 (−0.068, 0.077)        0.900          
  MMAS-8                  −0.22 (−0.419, −0.029)   −0.11 (−0.311, 0.085)                                       −0.10 (−0.295, 0.100)       0.332          
  WHOQoL-BREF             −0.06 (−0.107, −0.021)   −0.05 (−0.103, −0.005)                                      −0.06 (−0.105, −0.007)      0.024          
  **SBP**                                          **n**=**623**[‡](#tfn8-tcrm-11-669){ref-type="table-fn"}    **n**=**623**^‡‡^                          
  Intercept               --                       --                                                          146.97 (136.544, 157.397)   \<0.0001       0.166
  DDS-17                  −0.17 (−0.255, −0.089)   −0.09 (−0.174, −0.008)                                      −0.08 (−0.161, 0.005)       0.066          
  **LDL-C**                                        **n**=**401**[§](#tfn9-tcrm-11-669){ref-type="table-fn"}    **n**=**401**^§§^                          
  Intercept               --                       --                                                          3.87 (3.018, 4.719)         \<0.0001       0.052
  PHQ-9                   0.03 (0.007, 0.044)      0.02 (0.000, 0.044)                                         0.02 (−0.001, 0.043)        0.061          
  MMAS-8                  −0.07 (−0.133, −0.015)   −0.04 (−0.110, 0.030)                                       −0.03 (−0.103, 0.037)       0.356          
  **Triglycerides**                                **n**=**551**[‖](#tfn10-tcrm-11-669){ref-type="table-fn"}   **n**=**551**^‖‖^                          
  Intercept               --                       --                                                          2.74 (1.809, 3.660)         \<0.0001       0.073
  Physician distress      −0.03 (−0.049, −0.003)   −0.02 (−0.046, −0.001)                                      −0.02 (−0.046, 0.002)       0.072          
  **Total cholesterol**                            **n**=**569**[¶](#tfn11-tcrm-11-669){ref-type="table-fn"}   **n**=**569**^¶¶^                          
  Intercept               --                       --                                                          7.06 (5.816, 8.311)         \<0.0001       0.082
  PHQ-9                   0.04 (0.014, 0.056)      0.02 (−0.006, 0.043)                                        0.01 (−0.011, 0.039)        0.265          
  MMAS-8                  −0.11 (−0.177, −0.046)   −0.07 (−0.139, 0.001)                                       −0.06 (−0.131, 0.009)       0.086          
  WHOQoL-BREF             −0.02 (−0.030, −0.001)   −0.02 (−0.033, 0.001)                                       −0.02 (−0.032, 0.001)       0.070          

**Notes:** Variables in the model include:

age, diabetes duration, HPT duration, retinopathy, OHA, insulin;

diabetes duration, HPT, insulin, AHA agents;

age, ethnic, HPT, dyslipidemia, OHA, AHA agents

age, diabetes duration, HPT duration, ischemic heart disease, insulin;

age, gender, employment, OHA, insulin, LLA;

age, OHA, insulin, exercise, ischemic heart disease;

^\*\*,\ ††,\ ‡‡,\ §§,\ ‖‖\ and\ ¶¶^In these models, health clinic is added.

**Abbreviations:** DDS-17, 17-item Diabetes Distress Scale; PHQ-9, 9-item Patient Health Questionnaire; MMAS-8, 8-item Morisky Medication Adherence Scale; WHOQoL-BREF, World Health Organization Quality of Life-Brief 26 items; HPT, hypertension; OHA, oral hypoglycemic agent; AHA, antihypertensive agent; LLA, lipid-lowering agent; APA, anti-platelet agent; CI, confidence interval; HbA~1c~, glycated hemoglobin.
